← Back to patent-cliff list
Praziquantel / repurposed undisclosed anti-inflammatory drug (Drugs for Neglected Diseases initiative)
Tier C — Watch / tradePraziquantel / repurposed undisclosed anti-inflammatory drug (Drugs for Neglected Diseases initiative)
Drugs For Neglected Diseases Initiative
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：血吸虫病
Regional status
US
-
EU
Phase III
2025-12-31
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Praziquantel / repurposed undisclosed anti-inflammatory drug (Drugs for Neglected Diseases initiative)?
Approved indications include: 血吸虫病.
When does the Praziquantel / repurposed undisclosed anti-inflammatory drug (Drugs for Neglected Diseases initiative) patent expire?
No public expiry year is available for Praziquantel / repurposed undisclosed anti-inflammatory drug (Drugs for Neglected Diseases initiative) yet; this page updates once verified.
How do I get a quote for Praziquantel / repurposed undisclosed anti-inflammatory drug (Drugs for Neglected Diseases initiative) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29